Brokers Issue Forecasts for uniQure FY2025 Earnings

uniQure (NASDAQ:QURE) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for uniQure in a research note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings of ($2.76) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share.

A number of other analysts have also weighed in on QURE. Guggenheim reaffirmed a “buy” rating and set a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of uniQure in a research note on Monday, April 21st. Chardan Capital restated a “buy” rating and set a $38.00 price target on shares of uniQure in a report on Monday, May 12th. StockNews.com raised uniQure to a “sell” rating in a research report on Tuesday, March 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.82.

uniQure Price Performance

QURE opened at $15.31 on Wednesday. The stock’s 50-day moving average price is $12.37 and its 200 day moving average price is $12.45. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The firm has a market cap of $838.62 million, a price-to-earnings ratio of -3.09 and a beta of 0.10. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $5.93 million.

Insider Activity at uniQure

In other uniQure news, CFO Christian Klemt sold 14,341 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the transaction, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at approximately $1,630,380.40. This trade represents a 8.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 6,717 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the transaction, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at $6,574,599.40. The trade was a 1.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock worth $961,401 over the last three months. 4.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Woodline Partners LP grew its stake in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares during the last quarter. 683 Capital Management LLC lifted its holdings in shares of uniQure by 1.6% in the first quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company’s stock valued at $16,430,000 after purchasing an additional 25,000 shares in the last quarter. Vestal Point Capital LP grew its position in shares of uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after purchasing an additional 1,767,572 shares during the last quarter. Birchview Capital LP increased its stake in shares of uniQure by 343.5% during the 1st quarter. Birchview Capital LP now owns 88,697 shares of the biotechnology company’s stock worth $940,000 after purchasing an additional 68,697 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its stake in shares of uniQure by 3.8% during the 1st quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after purchasing an additional 101,598 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.